Successful Treatment of Patients With Newly Diagnosed/Untreated Light Chain Multiple Myeloma With a Combination of Bendamustine; Prednisone and Bortezomib (BPV)

Mrachacz, H.; Khoder, N.; Plötze, Madlen; Holzvogt, Bruno; Andrea, Marc; Schliwa, Thomas; Heyn, Simone; Pfrepper, Christian; Franke, Georg-Nikolaus; Krahl, Rainer; Jentzsch, Madlen; Leiblein, Sabine; Schwind, Sebastian; Vučinić, Vladan; Niederwieser, Dietger; Poenisch, Wolfram

doi:10.1016/j.clml.2015.07.386

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most common severe side effects were grade III-IV leukopenia in 22.2% patients and grade III-IV thrombocytopenia in 13.3% patients. Moderate to severe infection was seen in 22.2% patients (Table 2 ) [ 21 - 22 ].…”

Section: Reviewmentioning

confidence: 99%

See 1 more Smart Citation

An Overview of Light Chain Multiple Myeloma: Clinical Characteristics and Rarities, Management Strategies, and Disease Monitoring

Rafae¹,

Malik²,

Zar³

et al. 2018

Cureus

View full text Add to dashboard Cite

Light chain multiple myeloma (LCMM) constitutes approximately 15% of patients with multiple myeloma (MM). It has a poorer prognosis when compared to immunoglobulin (Ig) G or IgA variant. We performed a comprehensive literature search on LCMM and identified a total of 390 articles. After a detailed screening, six studies involving a total of 1054 LCMM patients were included. A literature review revealed bone pain and renal failure as the most common initial sign and symptoms while extramedullary disease (EMD) was acquired later during the progression of the disease. Bortezomib has shown superior efficacy in LCMM patients over nonbortezomib regimens as demonstrated by better overall response rate (95.5% vs. 60%), progression-free survival (PFS) (25% vs. 9% at two years), and overall survival (OS) (24% vs. 9% at five years). Moreover, better PFS was seen, when bortezomib was used in combination with bendamustine compared to dexamethasone (95% vs. 25% at two years). Similarly, better OS (90% at two years) was observed with bortezomib in combination with bendamustine. Monitoring of disease should include serum free light chain levels, as literature review revealed that serum assays were more sensitive in indicating the disease and predicting PFS and OS as compared to urine assays. We provide presentation patterns, clinical rarities, management strategies including their efficacy, and disease monitoring in patients with LCMM in our review paper.

show abstract

Section: Reviewmentioning

confidence: 99%

“…In the study by Mrachacz et al (2015) and Tessenow et al (2017) patients treated with a combination of bortezomib, bendamustine (B), and prednisone (P) showed an ORR of > 95% (Table 2 ) [ 21 - 22 ]. However, better PFS was seen, when bortezomib was used in combination with bendamustine compared to dexamethasone (95% vs. 25% at two years).…”

Section: Reviewmentioning

confidence: 99%